Elicio Therapeutics Presents Preclinical Data on its Lymph Node-Targeted SARS-CoV-2 Amphiphile Vaccine, ELI-005, at the 2022 Keystone Symposia on Viral Immunity: Basic Mechanisms and Therapeutic Applications

• The presented data show ELI-005 elicits strong and long-lasting cellular and humoral immune responses that were maintained at significantly higher levels than comparator vaccines over 32 weeks in mice.
  
• ELI-005, containing the lymph node-targeted Amphiphile vaccine adjuvant AMP-CpG, induced potent, comprehensive and persistent innate immune responses in draining lymph nodes in mice.
  
• Animals treated with AMP-CpG showed a significantly higher percentage of CD8⁺ T cells with central memory phenotype, which resulted in more robust recall responses one week after antigen challenge in mice.
  
• ELI-005 rapidly induced potent cellular and antibody responses in non-human primates up to 5,000-fold over baseline which exhibited cross-reactive neutralization activity specific to Beta, Delta and Omicron SARS-CoV-2 variants of concern.

Excerpt from the Press Release:

BOSTON, July 06, 2022 (GLOBE NEWSWIRE) — Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced the presentation of preclinical data on ELI-005, a protein subunit vaccine containing the spike receptor-binding domain (RBD) protein of SARS-CoV-2, and Elicio’s lymph node-targeted CpG TLR-9 agonist, Amphiphile-CpG (AMP-CpG), demonstrating they induce potent cross-reactive antibody and T cell responses in mice and non-human primates. ELI-005 yielded robust and durable cross-reactive serum IgG responses specific to several SARS-CoV-2 variants of concern alongside potent and cross-reactive peripheral T cell responses. The data were presented in three posters at the 2022 Keystone Symposia on Viral Immunity: Basic Mechanisms and Therapeutic Applications virtually and in-person at the Keystone Resort in Keystone, CO from June 29-July 2, 2022. The electronic presentations are accessible here.

While currently authorized vaccines have shown success in the reduction of severe disease risk from COVID-19, rapidly emerging viral variants continue to drive substantial pandemic waves of infection, resulting in numerous global public health challenges. Future advances in prophylactic vaccine activity will play a critical role in the resolution of the current pandemic and preparation for future pandemics driven by similar coronavirus pathogens. The robust immune responses generated by ELI-005 suggest that it may enhance broad protection against new variants of concern.

“We are pleased to present updated data from ongoing preclinical work in mice and non-human primates with ELI-005, our lymph node-targeting AMP-vaccine against SARS-CoV-2.

Click the button below to read the entire Press Release:

Continue Reading The Press Release